Share Twitter LinkedIn Facebook Email Daniel Pollyea, MD, Associate Professor/Clinical Director of Leukemia Services, Division of Hematology, University of Colorado School of Medicine, discusses prognostic factors in acute myeloid leukemia (AML) patients. Advertisement
Joe Biden Prostate Cancer Timeline: When Did It Begin? Experts Weigh In Acute Myelogenous Leukemia 4 Mins Read
Transforming AML Treatment: The Breakthrough Precision and Speed of Dr. Gabriel Mannis, MD on the Notable Platform Acute Myelogenous Leukemia 1 Min Read